文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

鞭毛蛋白以巨噬细胞依赖方式减轻实验性脓毒症

Flagellin attenuates experimental sepsis in a macrophage-dependent manner.
PubMed 文献 · Crit Care · 2019-04-03
一句话结论实验性脓毒症中,鞭毛蛋白经TLR5依赖的巨噬细胞途径增强细菌清除、减轻器官损伤并降低免疫细胞凋亡;脓毒症患者单核细胞TLR5表达升高与死亡率增加相关。

该研究评估鞭毛蛋白对实验性脓毒症生存、细菌负荷和组织损伤的影响,并探讨单核/巨噬细胞吞噬与杀菌作用。结果显示,治疗性给予鞭毛蛋白以Toll样受体5(TLR5)依赖方式增加细菌清除、减少器官炎症与损伤、降低免疫细胞凋亡;巨噬细胞而非中性粒细胞介导该获益,鞭毛蛋白诱导脓毒症小鼠巨噬细胞向M1极化,并直接增强巨噬细胞(而非中性粒细胞)的吞噬与杀菌,促进吞噬体形成和活性氧(ROS)水平升高。脓毒症患者循环单核细胞(而非中性粒细胞)表面TLR5表达显著升高,单核细胞TLR5高表达与死亡率增加、确诊菌血症和更高的序贯器官衰竭评估评分相关;鞭毛蛋白治疗可挽救死于脓毒症患者单核/巨噬细胞受损的吞噬与杀菌能力。作者认为这些发现确立了鞭毛蛋白作为免疫佐剂治疗脓毒症的潜在价值,并为基于单核细胞TLR5表达的靶向治疗策略提供了新见解。

要点

  • 实验性脓毒症中,治疗性给予鞭毛蛋白以TLR5依赖方式增加细菌清除、减少器官炎症与损伤、降低免疫细胞凋亡。
  • 巨噬细胞而非中性粒细胞介导鞭毛蛋白对实验性脓毒症的获益,鞭毛蛋白诱导脓毒症小鼠巨噬细胞向M1极化。
  • 鞭毛蛋白可直接增强巨噬细胞(而非中性粒细胞)的吞噬与杀菌,促进吞噬体形成并提高巨噬细胞内ROS水平。
  • 脓毒症患者循环单核细胞(而非中性粒细胞)表面TLR5表达显著升高,单核细胞TLR5高表达与死亡率增加、确诊菌血症和更高SOFA评分相关。
  • 鞭毛蛋白治疗可挽救死于脓毒症患者单核/巨噬细胞受损的吞噬与杀菌能力。

适用人群与场景

  • 实验性脓毒症模型(小鼠)及脓毒症患者来源的单核/巨噬细胞与中性粒细胞

研究设计与关键结果

  • 研究评估鞭毛蛋白给药对实验性脓毒症后生存、细菌负荷和组织损伤的影响,并检测对单核/巨噬细胞吞噬和杀菌的作用。
  • 治疗性给予鞭毛蛋白以Toll样受体5(TLR5)依赖方式增加细菌清除、减少器官炎症与损伤、降低免疫细胞凋亡。
  • 巨噬细胞而非中性粒细胞介导鞭毛蛋白对实验性脓毒症的获益,鞭毛蛋白诱导脓毒症小鼠巨噬细胞向M1极化。
  • 鞭毛蛋白治疗可直接增强巨噬细胞(而非中性粒细胞)的吞噬与杀菌,促进吞噬体形成并提高巨噬细胞内ROS水平。
  • 脓毒症患者循环单核细胞(而非中性粒细胞)表面TLR5表达显著升高;单核细胞TLR5高表达与死亡率增加、确诊菌血症和更高SOFA评分相关。
  • 鞭毛蛋白治疗可挽救死于脓毒症患者单核/巨噬细胞受损的吞噬与杀菌能力。

证据类型、等级与局限

  • 证据类型:实验性研究(动物实验与患者样本体外实验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现确立了鞭毛蛋白作为免疫佐剂治疗脓毒症的潜在价值,并为基于脓毒症患者单核细胞TLR5表达的靶向治疗策略提供了新见解。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis is the leading cause of death among critically ill patients, and no specific therapeutic agent is currently approved for the treatment of sepsis.

METHODS: We assessed the effects of flagellin administration on survival, bacterial burden, and tissue injury after sepsis. In addition, we examined the effects on phagocytosis and bacterial killing in monocytes/macrophages.

RESULTS: Therapeutic administration of flagellin increased bacterial clearance, decreased organ inflammation and injury, and reduced immune cell apoptosis after experimental sepsis, in a Toll-like receptor 5 (TLR5)-dependent manner. Macrophages, but not neutrophils, mediated the beneficial effects of flagellin on experimental sepsis, and flagellin induced macrophage polarization into M1 in septic mice. Flagellin treatment could directly enhance phagocytosis and bacterial killing of macrophages, but not neutrophils. Subsequent studies demonstrated that flagellin could promote phagosome formation and increase reactive oxygen species (ROS) levels in macrophages. Finally, we found that the expression of TLR5 was significantly elevated on the surface of circulating monocytes, but not neutrophils, from patients with sepsis. Higher expression levels of TLR5 on monocytes were associated with increased mortality, documented bacteremia, and higher Sequential Organ Failure Assessment scores of the septic patients. Moreover, flagellin treatment rescued the impaired phagocytosis and bacterial killing ability of monocytes/macrophages from patients who died of sepsis.

CONCLUSIONS: These novel findings not only established the potential value of application of flagellin as an immunoadjuvant in treating sepsis, but also provided new insights into targeted therapeutic strategy on the basis of monocyte TLR5 expression in septic patients.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Yang X, Yin Y, Yan X, et al. Flagellin attenuates experimental sepsis in a macrophage-dependent manner. Crit Care. 2019. PMID: 30944018. doi:10.1186/s13054-019-2408-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。